Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Aurinia Pharmaceuticals Inc. before investing.

In this article, we go over a few key elements for understanding Aurinia Pharmaceuticals Inc.’s stock price such as:

• Aurinia Pharmaceuticals Inc.’s current stock price and volume
• Why Aurinia Pharmaceuticals Inc.’s stock price changed recently
• Upgrades and downgrades for AUPH from analysts
• AUPH’s stock price momentum as measured by its relative strength

About Aurinia Pharmaceuticals Inc. (AUPH)

Before we jump into Aurinia Pharmaceuticals Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Want to learn more about Aurinia Pharmaceuticals Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Aurinia Pharmaceuticals Inc..

Aurinia Pharmaceuticals Inc.’s Stock Price as of Market Close

As of November 28, 2025, 1:00 PM, CST, Aurinia Pharmaceuticals Inc.’s stock price was $16.120.

Aurinia Pharmaceuticals Inc. is down 1.53% from its previous closing price of $16.370.

During the last market session, Aurinia Pharmaceuticals Inc.’s stock traded between $16.008 and $16.370. Currently, there are approximately 131.81 million shares outstanding for Aurinia Pharmaceuticals Inc..

Aurinia Pharmaceuticals Inc.’s price-earnings (P/E) ratio is currently at 29.8, which is high compared to the Biotechnology industry median of 19.9. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Aurinia Pharmaceuticals Inc. Stock Price History

Aurinia Pharmaceuticals Inc.’s (AUPH) price is currently up 22.4% so far this month.

During the month of November, Aurinia Pharmaceuticals Inc.’s stock price has reached a high of $16.480 and a low of $12.790.

Over the last year, Aurinia Pharmaceuticals Inc. has hit prices as high as $16.480 and as low as $6.550. Year to date, Aurinia Pharmaceuticals Inc.’s stock is up 79.51%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Aurinia Pharmaceuticals Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 26, 2025, there was 1 analyst who downgraded Aurinia Pharmaceuticals Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Aurinia Pharmaceuticals Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Aurinia Pharmaceuticals Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Aurinia Pharmaceuticals Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Aurinia Pharmaceuticals Inc. (AUPH) by visiting AAII Stock Evaluator.

Relative Price Strength of Aurinia Pharmaceuticals Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 26, 2025, Aurinia Pharmaceuticals Inc. has a weighted four-quarter relative price strength of 18.01%, which translates to a Momentum Score of 90 and is considered to be Very Strong.

Want to learn more about how Aurinia Pharmaceuticals Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Aurinia Pharmaceuticals Inc. Stock Price: Bottom Line

As of November 28, 2025, Aurinia Pharmaceuticals Inc.’s stock price is $16.120, which is down 1.53% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Aurinia Pharmaceuticals Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.